CareDx (CDNA) Expected to Announce Quarterly Earnings on Wednesday

CareDx (NASDAQ:CDNA - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 6th. Analysts expect CareDx to post earnings of $0.12 per share and revenue of $90.72 million for the quarter. CareDx has set its FY 2025 guidance at EPS.

CareDx (NASDAQ:CDNA - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.06 by $0.03. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The business had revenue of $84.69 million for the quarter, compared to analyst estimates of $84.56 million. During the same period in the previous year, the firm earned ($0.03) EPS. The business's revenue for the quarter was up 17.6% compared to the same quarter last year. On average, analysts expect CareDx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CareDx Stock Performance

CDNA stock traded down $0.05 during trading on Friday, hitting $12.79. The stock had a trading volume of 875,600 shares, compared to its average volume of 2,162,351. The company's 50 day moving average price is $17.88 and its two-hundred day moving average price is $19.21. CareDx has a 1-year low of $10.96 and a 1-year high of $34.84. The stock has a market cap of $712.15 million, a price-to-earnings ratio of 11.12 and a beta of 2.19.

Insider Buying and Selling

In other CareDx news, Director Peter Maag sold 10,000 shares of the stock in a transaction on Monday, July 7th. The stock was sold at an average price of $18.58, for a total value of $185,800.00. Following the sale, the director directly owned 308,846 shares of the company's stock, valued at $5,738,358.68. This trade represents a 3.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Hannah Valantine sold 10,570 shares of CareDx stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $19.16, for a total value of $202,521.20. Following the transaction, the director directly owned 38,994 shares in the company, valued at approximately $747,125.04. The trade was a 21.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 139,078 shares of company stock valued at $2,419,915 over the last three months. Corporate insiders own 4.40% of the company's stock.

Institutional Investors Weigh In On CareDx

A hedge fund recently raised its stake in CareDx stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of CareDx, Inc. (NASDAQ:CDNA - Free Report) by 11.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 133,966 shares of the company's stock after acquiring an additional 13,619 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.24% of CareDx worth $2,378,000 at the end of the most recent quarter.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Wall Street Zen downgraded shares of CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. HC Wainwright reaffirmed a "neutral" rating and set a $25.00 price objective on shares of CareDx in a research note on Monday, May 5th. Craig Hallum dropped their target price on shares of CareDx from $40.00 to $26.00 and set a "buy" rating for the company in a research report on Friday, July 18th. The Goldman Sachs Group decreased their price target on CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a report on Thursday, April 17th. Finally, Stephens reissued an "overweight" rating and set a $40.00 price target on shares of CareDx in a research report on Monday, May 5th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.33.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.